The study aims to see how well two medicine combinations, CHF 5993 and CHF 1535, help people with a lung disease called COPD. COPD, or Chronic Obstructive Pulmonary Disease, makes it hard to breathe. This is a phase III study, meaning it’s testing how well the medicines work in a large group of people. Participants will be split into two groups randomly and won’t know which medicine they receive, a method called double-blind.
The study lasts for about 52 weeks, with check-ups every 6 weeks. Participants will use an electronic diary to record symptoms and medicine use daily. Regular tests like lung function tests and heart checks will be done.
- This study lasts for about 1 year with regular visits every 6 weeks.
- Participants must have COPD and be at least 40 years old.
- Regular tests and diary entries are required.
To join, you must have had COPD for at least a year and be a current or past smoker. You can’t join if you have certain health problems or if you’re pregnant. The study checks for safety and how the medicine helps you breathe better.